Skip to main content

Table 2 Clinical outcomes and Complications during ICU stay after PS matching

From: Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study

Outcomes

Number of outcomes/Total number of patients

P-value

Odds Ratio (OR) (95%CI)

P-value $**

Enoxaparin

UFH

All thrombosis cases, n(%)a

3 (4.6)

11 (18.3)

0.02^^

4.10 (1.05,15.93)

0.04

Major bleeding, n(%)a

2 (3.1)

2 (3.4)

0.93**

1.10 (0.14,8.56)

0.93

All bleeding cases (major and minor), n(%)a

5 (7.7)

2 (3.1)

0.24**

0.40 (0.07,2.29)

0.31

Requiring blood products transfusion during ICU stay, n(%)a

4 (6.2)

10 (16.9)

0.06^^

2.98 (0.85,10.39)

0.09

Heparin-associated thrombocytopenia (HAT), n(%)a

11 (16.9)

7 (10.8)

0.31^^

0.48 (0.16,1.39)

0.17

Heparin-induced thrombocytopenia (HIT), n(%)a

1 (1.5)

0 (0.0)

0.32**

NC

NC

 

Enoxaparin

UFH

P-value

Hazard Ratio (HR) (95%CI)

P-value $

30-day mortality, n (%)a

20 (36.4)

27 (57.4)

0.03^^

0.90 (0.49, 1.64)

0.73

In-hospital mortality, n (%)a

21 (38.2)

28 (56.0)

0.07^^

1.18 (0.66, 2.13)

0.57

 

Enoxaparin

UFH

P-value

beta coefficient (Estimates) (95%CI)

P-value $*

Ventilator free days, Mean (SDa

15.3 (13.59)

11.8 (12.26)

0.08^

0.08 (-0.67,0.83)

0.83

ICU Length of Stay (Days), Median (Q1, Q3)a

8.0 (5.00, 15.00)

11.0 (6.00, 16.00)

0.19^

0.05 (-0.19,0.29)

0.66

Hospital Length of Stay (Days), Median (Q1, Q3)a

13.0 (9.00, 19.00)

19.0 (11.00, 25.00)

0.01^

0.22 (-0.03,0.48)

0.09

  1. NC Not computable due to low counts
  2. aDenominator of the percentage is the total number of patients
  3. *T -Test / ^ Wilcoxon rank sum test is used to calculate the P-value
  4. ^^ Chi-square test/** Fisher’s Exact test is used to calculate P-value
  5. $** Logistic regression is used to calculate the OR and p-value
  6. $ Cox proportional hazards regression analysis used to calculate HR and p-value
  7. $* Generalized linear model is used to calculate estimates and p-value